Your browser does not support JavaScript! MECLIZINE HYDROCHLORIDE TABLET [UDL LABORATORIES, INC.]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

MECLIZINE HYDROCHLORIDE tablet
[UDL Laboratories, Inc.]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL Abbreviated New Drug Application
Drug Label Sections

DESCRIPTION

Meclizine hydrochloride, an oral antiemetic, is a white, slightly yellowish, crystalline powder which has a slight odor and is tasteless. It has the following structural formula:

chemical structure

C25H27CIN2•2HCI•H2O M.W. 481.89

The chemical name is 1-(p-chloro-alpha-phenylbenzyl)-4-(m-methyl-benzyl) - piperazine dihydrochloride monohydrate.

Meclizine Hydrochloride Tablets are available in 12.5 mg, and *25 mg strengths for oral administration.

*Contains FD&C Yellow #5 (see PRECAUTIONS).

Each tablet contains the following inactive ingredients: colloidal silicon dioxide, lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, starch, and stearic acid. In addition, the 12.5 mg tablet contains FD&C Blue #1; and the 25 mg tablet contains D&C Yellow #10 and FD&C Yellow #5.

CLINICAL PHARMACOLOGY

Meclizine hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

INDICATIONS AND USAGE

For the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness.

CONTRAINDICATIONS

Meclizine hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it.

WARNINGS

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking the drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland. Do not give to children under 12 years of age unless directed by a doctor.

PRECAUTIONS

The Meclizine Hydrochloride Tablets, 25 mg contain FD&C Yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow #5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Usage in Children: Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended under 12 years of age.

Usage in Pregnancy:Pregnancy Category B. Reproduction studies in rats have shown cleft palates at 25-50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine hydrochloride increases the risk of abnormalities when administered during pregnancy.

Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine hydrochloride, or any other medication should be used during pregnancy only if clearly necessary.

ADVERSE REACTIONS

Drowsiness, dry mouth, and on rare occasions, blurred vision have been reported.

DOSAGE AND ADMINISTRATION

Motion Sickness: The initial dose of 25 to 50 mg meclizine hydrochloride, should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

HOW SUPPLIED:

Meclizine Hydrochloride Tablets, USP 12.5 mg - blue, oval tablets debossed with “034” on one side and “par” on the other side. Tablets may contain characteristic dye spots. They are available as follows:

NDC 51079-089-20 - Unit dose blister packages of 100 (10 cards of 10 tablets each).

Meclizine Hydrochloride Tablets, USP 25 mg - yellow, oval tablets debossed with “035” on one side and “par” on the other side. They are available as follows:

NDC 51079-090-20 - Unit dose blister packages of 100 (10 cards of 10 tablets each).

Store at controlled room temperature 15° to 30°C (59° to 86°F).

Manufactured by:
Par Pharmaceutical Companies, Inc.
Spring Valley, NY 10977

Distributed by:
UDL Laboratories, Inc.
Rockford, IL 61103

S-5278 R13
3/10

PRINCIPAL DISPLAY PANEL - 12.5 mg

NDC 51079-089-20

MECLIZINE HYDROCHLORIDE
TABLETS, USP
12.5 mg

100 Tablets (10 x 10)

Each tablet contains:
Meclizine HCl, USP . . . . . . 12.5 mg

USUAL DOSAGE: Read Accompanying Literature.

Store at controlled room temperature 15° to 30°C (59° to 86°F).

Manufactured by:
Par Pharmaceutical Companies, Inc.
Spring Valley, NY 10977

Rx only

S-5276 R7

Packaged and Distributed by:

UDL LABORATORIES, INC.

ROCKFORD, IL 61103

This unit dose package is not child resistant.

For institutional use only.

Keep this and all drugs out of the reach of children.

This container provides light-resistance.

See window for lot number and expiration date.

Meclizine Hydrochloride 12.5 mg Tablets
Unit Carton

PRINCIPAL DISPLAY PANEL - 25 mg

NDC 51079-090-20

MECLIZINE HYDROCHLORIDE
TABLETS, USP
25 mg

100 Tablets (10 x 10)

Each tablet contains:
Meclizine HCl, USP . . . . . . 25 mg

USUAL DOSAGE: Read Accompanying Literature.

CAUTION: This product contains FD&C Yellow
No. 5 (tartrazine) which may cause allergic type
reactions in certain susceptible individuals.

Store at controlled room temperature 15° to 30°C (59° to 86°F).

Manufactured by:
Par Pharmaceutical Companies, Inc.
Spring Valley, NY 10977

Rx only

S-5277 R7

Packaged and Distributed by:

UDL LABORATORIES, INC.

ROCKFORD, IL 61103

This unit dose package is not child resistant.

For institutional use only.

Keep this and all drugs out of the reach of children.

This container provides light-resistance.

See window for lot number and expiration date.

Meclizine Hydrochloride 25 mg Tablets
Unit Carton
MECLIZINE HYDROCHLORIDE 
meclizine hydrochloride tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:51079-090
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
MECLIZINE HYDROCHLORIDE (MECLIZINE) MECLIZINE HYDROCHLORIDE25 mg
Inactive Ingredients
Ingredient NameStrength
ANHYDROUS LACTOSE 
CELLULOSE, MICROCRYSTALLINE 
SODIUM STARCH GLYCOLATE TYPE A POTATO 
STARCH, CORN 
STEARIC ACID 
WATER 
ISOPROPYL ALCOHOL 
D&C YELLOW NO. 10 
MAGNESIUM STEARATE 
COLLOIDAL SILICON DIOXIDE 
Product Characteristics
ColorYELLOWScoreno score
ShapeOVALSize6mm
FlavorImprint Code Par;035
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:51079-090-20100 in 1 BOX, UNIT-DOSE
1NDC:51079-090-011 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA08712805/13/2011
MECLIZINE HYDROCHLORIDE 
meclizine hydrochloride tablet
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:51079-089
Route of AdministrationORALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
MECLIZINE HYDROCHLORIDE (MECLIZINE) MECLIZINE HYDROCHLORIDE12.5 mg
Inactive Ingredients
Ingredient NameStrength
ANHYDROUS LACTOSE 
CELLULOSE, MICROCRYSTALLINE 
SODIUM STARCH GLYCOLATE TYPE A POTATO 
FD&C BLUE NO. 1 
WATER 
ISOPROPYL ALCOHOL 
STARCH, CORN 
STEARIC ACID 
MAGNESIUM STEARATE 
COLLOIDAL SILICON DIOXIDE 
Product Characteristics
ColorBLUEScoreno score
ShapeOVALSize5mm
FlavorImprint Code Par;034
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:51079-089-20100 in 1 BOX, UNIT-DOSE
1NDC:51079-089-011 in 1 BLISTER PACK
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA08712705/13/2011
Labeler - UDL Laboratories, Inc. (039615992)
Registrant - UDL Laboratories, Inc. (039615992)
Establishment
NameAddressID/FEIBusiness Operations
Par Pharmaceutical, Inc.092733690MANUFACTURE
Establishment
NameAddressID/FEIBusiness Operations
UDL Laboratories, Inc.039615992REPACK, RELABEL

Revised: 3/2010
 
UDL Laboratories, Inc.

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services